SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-003415 to Kodiak Sciences Inc. (KOD) (CIK 0001468748) (KOD)

Kodiak Sciences Inc. (KOD) (CIK 0001468748)
Date: April 5, 2023 · CIK: 0001468748 · Accession: 0000000000-23-003415

AI Filing Summary & Sentiment

File numbers found in text: 333-271043

Date
April 5, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Kodiak Sciences Inc. (KOD) (CIK 0001468748)

Letter

United States securities and exchange commission logo April 5, 2023 D. Victor Perlroth, M.D. Chairman and Chief Executive Officer Kodiak Sciences Inc. 1200 Page Mill Road Palo Alto, California 94304 Re:Kodiak Sciences Inc. Registration Statement on Form S-3 Filed March 31, 2023 File No. 333-271043 Dear D. Victor Perlroth: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anitha Anne

Show Raw Text
United States securities and exchange commission logo
April 5, 2023
D. Victor Perlroth, M.D.
Chairman and Chief Executive Officer
Kodiak Sciences Inc.
1200 Page Mill Road
Palo Alto, California 94304
Re:Kodiak Sciences Inc.
Registration Statement on Form S-3
Filed March 31, 2023
File No. 333-271043
Dear D. Victor Perlroth:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Anitha Anne